Mode
Text Size
Log in / Sign up

Cervical cancer patients face mean treatment delays of 71.42 days from histopathological diagnosisCervical cancer treatment delays average 71 days

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that cervical cancer treatment often exceeds the 60-day benchmark, especially in upper-middle-income countries.

This meta-analysis synthesizes global data regarding the duration between histopathological diagnosis and the initiation of first-line definitive treatment for patients with cervical cancer. The study focuses on identifying systemic delays that may impact clinical outcomes.

The pooled mean delay from diagnosis to treatment initiation was 71.42 days (95% CI: 47.96-94.88), which exceeds the established benchmark of 30 to 60 days. Specific findings indicate that 59% of patients experienced delays exceeding 30 days, while 33% faced delays longer than 90 days. Treatment modalities showed varying wait times: radiotherapy had a mean delay of 79.90 days, the longest among reported types.

Geographic and economic disparities were evident in the results. Patients in high-income countries experienced a mean delay of 40.50 days, whereas patients in upper-middle-income countries faced a significantly longer wait of 94.63 days. The authors noted high heterogeneity (I2 = 99.98%) in the data.

These findings highlight significant barriers to timely treatment, particularly in upper-middle-income regions and for radiotherapy patients. These results may inform policy interventions aimed at reducing delays to meet international benchmarks.

How this fits prior evidence

This meta-analysis addresses a gap regarding systemic barriers to care by quantifying the time from diagnosis to treatment initiation. While previous coverage identified psychosocial and systemic factors influencing screening uptake in women living with HIV, this study provides specific data on post-diagnosis treatment delays. It identifies that 59% of patients experience delays over 30 days, highlighting significant hurdles in the clinical pathway.

A new review of studies from around the world finds that women with cervical cancer often wait more than two months before starting treatment. The average delay from diagnosis to the start of surgery, chemotherapy, or radiation was about 71 days, which is longer than the recommended 30 to 60 days. This delay was even longer in upper-middle-income countries, where the average wait was nearly 95 days, compared to about 40 days in high-income countries.

The review combined data from many studies, including women who were newly diagnosed and waiting for their first treatment. It found that more than half of patients (59%) waited more than 30 days, and about a third (33%) waited more than 90 days. Among different treatment types, radiation therapy had the longest average delay at about 80 days.

It's important to note that this is a meta-analysis of observational studies, not a clinical trial. The results show a link between where a person lives and how long they wait, but they don't prove that these delays cause worse outcomes. The studies also varied widely, which makes the findings less precise.

The main takeaway is that many women face long waits for cervical cancer treatment, especially in certain regions. This highlights a need for health systems to improve access and reduce delays. If you or someone you know is waiting for cancer treatment, talk to your doctor about any concerns and what to expect.

What this means for you:
Many women with cervical cancer wait over two months for treatment, with longer delays in middle-income countries.

Common questions

How long is the average delay for cervical cancer treatment?

The average delay from diagnosis to starting treatment is about 71 days, according to a review of studies worldwide. That's longer than the recommended 30 to 60 days. More than half of patients waited over 30 days, and about a third waited over 90 days.

Does the delay differ by country income level?

Yes. In high-income countries, the average delay was about 40 days. In upper-middle-income countries, it was much longer, about 95 days. This suggests that where you live can affect how quickly you get treatment.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Cervical cancer disproportionately affects women in LMICs, with treatment delays worsening outcomes. Despite WHO's 90-70-90 elimination goal, global disparities persist. This study systematically reviews worldwide delays from diagnosis to treatment, identifying contributing factors across income levels, healthcare systems, and treatment approaches. METHOD: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Observational studies reporting the interval between histopathological diagnosis of cervical cancer and initiation of first-line definitive treatment (surgery, chemotherapy, radiotherapy, or combination therapy) were eligible. Search was performed in PubMed, Embase, Web of Science, and Scopus up to October 30, 2025. Two reviewers independently screened records, extracted data, and assessed study quality using the JBI Critical Appraisal Checklist. Pooled mean delays were estimated using random-effects models in STATA 19.5. Subgroup analyses and meta-regression explored heterogeneity by income level, data source, and treatment modality. Sensitivity analyses and publication bias assessments were performed using Galbraith plots, leave-one-out methods, Egger's test, and trim-and-fill procedures. RESULT: The pooled mean delay from diagnosis to treatment initiation was 71.42 days (95% CI: 47.96-94.88), exceeding recommended benchmarks of 30-60 days. Across studies, 59% of patients experienced treatment initiation delays exceeding 30 days, 54% exceeded 45 days, and 33% exceeded 90 days. Subgroup analysis revealed that high-income countries experienced shorter delays (40.50 days), while upper-middle-income countries faced significantly longer waits (94.63 days). Among treatment types, radiotherapy had the longest delay (79.90 days). The causes of delay were multifaceted, involving patient-level challenges such as stigma and financial constraints, systemic issues like inefficient referral processes and limited radiotherapy access, and disease-related factors. Despite substantial heterogeneity across studies (I² = 99.98%), sensitivity analyses validated the consistency and reliability of the pooled estimates. CONCLUSION: This study provides the most comprehensive global estimate of cervical cancer treatment delays to date. The findings highlight critical disparities across income settings and healthcare systems, with actionable insights for policy and practice. Addressing these delays is essential to improving survival outcomes and achieving WHO's cervical cancer elimination targets. Strengthening referral systems, expanding radiotherapy infrastructure, and tailoring interventions to local barriers are key priorities.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.